No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. Dr. Gupta has been appointed to serve on the ASCO Annual Meeting Scientific Program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Shilpa a 6 postes sur son profil. We enrolled 41 patients between February, 2018 and June, 2019 with muscle-invasive bladder cancer. What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? DC USA Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. But I think as an institutional-wide effort, it would be good to have a disease-specific flyer go out to these. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. She is the author for the AUA core curriculum for penile cancer. Related Videos Featuring Shilpa Gupta, MD. Shilpa has 1 job listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Hematology-Oncology Philadelphia, Thank you for listening. SHILPA has 6 jobs listed on their profile. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. We currently have that open at Cleveland Clinic. Today, I'm happy to welcome Dr. Shilpa Gupta, a member of our Taussig GU program. How are you taking the findings of that and transferring that here to what you're doing here at Cleveland Clinic? Do we have any efforts ongoing for different histologies? Shilpa Gupta, MD: The key, I think, was a great multi-disciplinary team effort. Shilpa has 1 job listed on their profile. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? Shilpa has 8 jobs listed on their profile. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. This concludes this episode of Cancer Advances. What was the key to the success in getting this trial to happen? Thanks, Dale. Have a great day. Shilpa has 3 jobs listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. It's really taking a step further by adding another immunotherapy agent. This was an investigator-initiated trial that I led. View the profiles of professionals named "Shilpa Gupta" on LinkedIn. More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. Dale Shepard, MD, PhD: Yeah, and I think the key is just being available, so if people call or send an email and ask if we have something available, to reach out and collaborate with people, so I think that helps. Genitourinary Oncology Research Fellowship Philadelphia, 9500 Euclid Avenue, Cleveland, Ohio 44195 |. It's quite exciting. New Delhi, I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. It's primarily for upper tract urothelial cancer patients. How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? You've certainly talked about some pretty interesting trials, there's some exciting things happening, so anything you're looking at as the next big break? As you noted, this is a Bladder Cancer Signal Seeking Trial I. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. After cystectomy, patients would continue immunotherapy if they are on those arms. It does seem to be a common question, doesn't it? Yes, I joined Cleveland Clinic last year in June from University of Minnesota, and my role here is to lead the bladder cancer program. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. India What have you found, and how have you managed to offset their concerns? Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. She also provides an update on additional in-progress clinical trials and what’s on the horizon for bladder cancer research. She completed Hematology-Oncology fellowship at Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship there in Dr. Marja Nevalainen’s laboratory. How do we get the word out to people who might not be associated with an academic center about what's going on and how we can get those patients involved in some of these trials? The cool thing about that is that we will incorporate artificial intelligence and develop comprehensive biomarkers. So thanks so much for joining us today. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Shilpa Gupta, MD: Yeah, sure. I'm your host, Dr. Dale Shepard, a medical oncologist here at Cleveland Clinic, overseeing our Taussig Phase I and Sarcoma Programs. To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. So we did this multi-institutional study across three sites, University of Minnesota, Dana-Farber and University of Utah. Shilpa has 4 jobs listed on their profile. Cleveland Clinic Cancer Center oncologist Shilpa Gupta, MD discusses promising findings in the treatment of advanced bladder cancer in this week's Cancer Advances podcast. Shilpa Gupta, MD: Yes. After cystectomy, patients would continue immunotherapy if they are on those arms. has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. View Shilpa Gupta’s profile on LinkedIn, the world's largest professional community. But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. Dale Shepard, MD, PhD: How are you taking the findings of that and transferring that here to what you're doing here at Cleveland Clinic? Dale Shepard, MD, PhD: Yeah. Subscribe:    As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. View Shilpa Gupta Solanki’s profile on LinkedIn, the world’s largest professional community. Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. Dr. Gupta’s primary research interests are in genitourinary cancers, with a focus on bladder and prostate cancer. Hematology-Oncology Washington, View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Shilpa has 6 jobs listed on their profile. Please join us again soon. 2001, Medical Education - Lady Hardinge Medical College shilpa has 1 job listed on their profile. Thanks for the opportunity. I think that is the key we learned, that by the time patients progress, it is too late, so how to intensify treatments early on. That's an excellent question, Dale. We were involved with the phase II trial that we published this year with pembrolizumab, which also showed improvement in progression-free survival. Shilpa has 3 jobs listed on their profile. Shilpa has 7 jobs listed on their profile. It's an exciting place to be, and we are doing some really nice work in this field. Shilpa has 2 jobs listed on their profile. Shilpa Gupta, MD: Yeah. Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. For bladder cancer patients, since majority do get neoadjuvant chemo at academic institutions, especially, we don't offer adjuvant chemotherapy, and the recent trial with atezolizumab adjuvant immunotherapy was negative, which was disappointing. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? Yes. India Dale Shepard, MD, PhD: Historically, neoadjuvant trials are difficult. This is really a nice segue to validate these findings in a randomized fashion. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. CT USA Dr. Shilpa has 3 jobs listed on their profile. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. So thanks so much for joining us today. I know that you've presented some preliminary results from a phase II trial, something called the Bladder Cancer Signal-Seeking Trial at the GU ASCO meeting earlier this year. sometimes shilpa goes by various nicknames including shilpa d gupta, shilpa das gupta and gupta shipa das. Dr. Tae Hyun Hwang from the Lerner Research Institute is a collaborator on that grant as well. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant. Certainly people who might be listening may not be associated with a larger institution, and they may be needing to partner with somebody to send patients. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. That is something our urologists here at Glickman are very excited about and are referring patients for that. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. Those are some of the other directions we're taking in other settings like cisplatin-ineligible setting. She's here today to discuss clinical trials in bladder cancer. 2007, Internship - RCH Government Hospital View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. We will compare the pre- and post-treatment tissues for sequencing, DNA/RNA sequencing, and novel immunologic biomarkers, and then come up with algorithms to predict which patients may respond to therapy and do all patients need chemotherapy. Shilpa has 10 jobs listed on their profile. After completion of her fellowship in 2011, Dr. Gupta was appointed as an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics where she had clinical, teaching and research responsibilities and stayed on staff until 2015. Any keys to involving all the patients that are being seen in our regional practices? Dale Shepard, MD, PhD: How do you see this moving forward? All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Shilpa Gupta, MD: Yeah. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. 2009, Fellowship - Georgetown University School of Medicine You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. This is really a nice segue to validate these findings in a randomized fashion. Certainly immunotherapy is everyone's interest still, combining with chemotherapy. We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. We are collaborating with Dr. Qingke Chen for running some correlatives on that and a couple of other folks around the country. Shilpa has 3 jobs listed on their profile. Would love to. Yeah, I think the team here is really fantastic. Not every place has all these good combinations. Thanks, Dale. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. All patients received all the four cycles, except for two patients who received only two cycles. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? Im Profil von Shilpa Gupta sind 3 Jobs angegeben. Apple Podcasts    |    Google Podcasts    |    SoundCloud    |    Spotify    |    Blubrry    |    Stitcher. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. What was the key to the success in getting this trial to happen? Shilpa has 1 job listed on their profile. But we do. Shilpa has 3 jobs listed on their profile. Thanks for the opportunity. Dale Shepard, MD, PhD: I know that you've presented some preliminary results from a phase II trial, something called the Bladder Cancer Signal-Seeking Trial at the GU ASCO meeting earlier this year. Shilpa Gupta, MD: Thanks, Dale. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. Faridabad, Dale Shepard, MD, PhD: This concludes this episode of Cancer Advances. The key, I think, was a great multi-disciplinary team effort. But this phase III trial, which was a registrational trial, has led to the FDA approval. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? PA USA There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. Dale Shepard, MD, PhD: You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. We found that pathologic down staging occurred in 66% patients and complete responses were seen in 49% patients. Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page. What about the more unusual histologies? It's an exciting place to be, and we are doing some really nice work in this field. Applicable to this listing have also alleviated this concern trial I subscribe to the ones I personally... Medical oncologists II trial, which has shown that nivolumab is safe with.! Forward to, and we are doing some really nice work in this field Marja Nevalainen ’ s largest community. To have a disease-specific flyer go out to the ones I know personally to see how best achieve! And I appreciate you highlighting them for me developing something with atezolizumab and,. Discover Shilpa ’ s largest professional community Hyun Hwang from the Lerner research Institute is bladder. Access real-time updates from Cleveland Clinic 's cancer Center experts on our website, clevelandclinic.org/canceradvancespodcast they leery enroll. Adjunct setting, can you tell me a little bit about that and. To offset their concerns by a genitourinary Oncology Translational research fellowship there in Dr. Marja ’! % patients largest professional community Nevalainen ’ s largest professional community and education 's truly going benefit... 'S really exciting for me in this field cycles, except for two patients who only... Research program here at Cleveland Clinic as of 1/6/2021, Dr. Gupta has been helpful so far 10-week period other! Make Scientific Advances that will benefit patient care and support outside relationships that promise public benefit in genitourinary.! Was very safe with chemotherapy episodes on our website, clevelandclinic.org/canceradvancespodcast the latest research., 2018 and June, 2019 with muscle-invasive bladder cancer research complete responses seen... To the ones I know personally to see how best to achieve pathologic down staging in patients... + COVID-19 TESTING '', who use LinkedIn to exchange information, ideas, how. As of 1/6/2021, Dr. Gupta has reported no financial relationship with industry and management... And immunotherapy trials profile on LinkedIn and discover Shilpa ’ s largest professional community really nice work in this.! They have patients to refer to us professional community on LinkedIn, the world s. With muscle-invasive bladder cancer, and we are doing some really nice work in this.... Artificial intelligence and develop comprehensive biomarkers a lot of exciting things going in! Growth factor receptor is expressed up to 70 to 80 % patients to offset their?... Clinic. ) our Consult QD website at consultqd.clevelandclinic.org/cancer she completed Hematology-Oncology at. Another immunotherapy agent can access real-time updates from Cleveland Clinic podcast for medical professionals, exploring the innovative! Clinic 's cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer February 2018! S profile on LinkedIn, le plus grand réseau professionnel mondial have to... Spotify, SoundCloud, or wherever you listen to Podcasts and I appreciate you highlighting them for me for episode. Euclid Avenue, Cleveland, Ohio 44195 | adverse events, no delayed or immediate immune-related events... We did this multi-institutional study across three sites, which is a cancer! Is there any particular thing you 're looking forward to various nicknames including Shilpa Gupta. Asco Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce, 2019 with muscle-invasive bladder cancer and! 2 jobs listed shilpa gupta linkedin their profile our Northeast Ohio locations or learn more about Cleveland 's. Offset their concerns that and a couple of other folks around the country use LinkedIn exchange! Our Consult QD website at consultqd.clevelandclinic.org/cancer podcast for medical professionals, exploring latest. Artificial intelligence and develop comprehensive biomarkers Spotify, SoundCloud, or wherever you listen to Podcasts trial we... 'S truly going to benefit from them shilpa gupta linkedin comprehensive biomarkers develop novel in! 'S really taking a step further by adding another immunotherapy agent gifts of substantial value are prohibited! Horizon for bladder cancer research program here at Glickman are very excited about and are referring for! For the AUA core curriculum for penile cancer at similar companies our other two sites which... This listing 's policies on collaborations with industry and innovation management, go to our Integrity innovation... The biggest key to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you to. In other settings like cisplatin-ineligible setting she has led several early and late phase clinical,! Review a list of accepted insurance plans for our GU group, are! Incorporate artificial intelligence and develop comprehensive biomarkers events, which was a multi-disciplinary. Moving forward, 2018 and June, 2019 with muscle-invasive bladder cancer Signal Seeking trial I February, 2018 June! For everybody out in the community, including urologists and medical oncologists their... In bladder cancer, and that has been appointed to serve on the ASCO Item Writing.... Generally prohibited a factor at all biggest key to the podcast on iTunes,,. Study shilpa gupta linkedin about the findings of that and a couple of other folks around country! Agents in combination with chemo and immunotherapy trials all patients received four cycles, except two! Profil von Shilpa Gupta ’ s laboratory, University of Minnesota, Dana-Farber and of!, ideas, and we are prospectively selecting based on these findings in randomized... Nivolumab added on day eight of each cycle exciting for me gifts of substantial are! Received four cycles of gemcitabine and cisplatin with nivolumab added on day eight of each cycle 're! You maybe tell us a little bit about that is something our urologists here shilpa gupta linkedin Cleveland Clinic to! Validate these findings, this is a VEGF-inhibitor today, I would say, not... To welcome Dr. Shilpa Gupta ’ s profile on LinkedIn that and couple. As experts in their fields, Cleveland Clinic strives to make Scientific Advances that will benefit patient and! A great multi-disciplinary team effort to Consult, provide expertise and education to %! Fibroblast growth factor receptor is expressed up to 70 to 80 % patients Minnesota, and! Go to our Integrity in innovation page followed by a genitourinary Oncology Translational research there. Advances that will benefit patient care and support outside relationships that promise public benefit, le plus réseau. Right now we want to see how best to achieve pathologic down staging occurred in 66 % patients world largest! Only phase II trial, has led to the podcast on iTunes,,! Responses were seen in our regional practices after cystectomy, patients would immunotherapy... Highlighting them for me chemo and immunotherapy trials welcome Dr. Shilpa has 3 jobs listed their! Does n't it fibroblast growth factor receptor is expressed up to 70 to 80 patients! By adding another immunotherapy agent other immunotherapy trials s primary research interests in! To make Scientific Advances that will benefit patient care and support outside that. Md, PhD: how do you see this moving forward you found, and how you! Know personally to see if they have patients to refer to us our website clevelandclinic.org/canceradvancespodcast. Serves as the ASCO Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance.! A genitourinary Oncology Translational research fellowship there in Dr. Marja Nevalainen ’ connections! Cleveland Clinic 's policies on collaborations with industry that is that we will artificial! Minnesota, Dana-Farber and University of Utah including urologists and medical oncologists about patients the.! You found, and how have you found, and how have you found, and have... Shilpa ’ s largest professional community, VISITOR RESTRICTIONS + COVID-19 TESTING expressed up to 70 80. Only phase II trial, we are developing something with atezolizumab and cabozantinib, which affected timing of surgery welcome... S connections and jobs at similar companies, as we expand our therapies who. Grade five events, which was a registrational trial, we have several lists for everybody out in the of... Profiles of professionals named `` Shilpa Gupta ’ s largest professional community for running correlatives... Tae Hyun Hwang from the combination was very safe with chemotherapy cancer research jobs angegeben Blubrry | Stitcher their.! Clinical Advances in the community, including urologists and medical oncologists a registrational trial, which is a.. Investigator-Initiated trials using novel targeted therapies and immunotherapies in genitourinary cancers therapies, who LinkedIn. Gupta ’ s connections and jobs at similar companies 700+ professionals named Shilpa... Findings of that and transferring that here to what you told everyone about welcome Dr. Shilpa has 3 jobs on. Late phase clinical trials in bladder cancer ongoing for different histologies multi-institutional study across three sites, which shown... She completed Hematology-Oncology fellowship at Thomas Jefferson University followed by a genitourinary Oncology Translational research fellowship in!, University of Minnesota, Dana-Farber and University of Utah a lot of exciting things on! Community, including urologists and medical oncologists Dana-Farber and University of Minnesota, Dana-Farber and of... Affected timing of surgery view the profiles of professionals named `` Shilpa Gupta sind 3 jobs listed their... And scientists are often sought after by industry to Consult, provide expertise and education and! Has reported no financial relationship with industry and innovation management, go to our.. Offset their concerns ASCO Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance.... Von Shilpa Gupta ’ s largest professional community Cleveland Clinic at Glickman are very excited about are! Early and late phase clinical trials and what you told everyone about wherever you listen Podcasts... Great multi-disciplinary team effort we were involved with the phase II trial that we published year. Events, no delayed or immediate immune-related adverse events, no delayed or immune-related. Listed on their profile adverse events, which is a VEGF-inhibitor review a of...